MapLight Therapeutics fires CFO Vishwas Setia for HR violation; interim CFO named

MapLight Therapeutics, Inc.

Vishwas Setia separated as CFO effective June 18, 2026, due to human resources violation; no severance paid.
Separation is unrelated to financial/operational results, internal controls, or clinical programs.
Jonathan Gillis, Chief Administrative and Accounting Officer, appointed interim CFO and principal financial officer.
Gillis continues as principal accounting officer; background in April 2026 proxy statement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vishwas Setia

Chief Financial Officer

MPLT · MapLight Therapeutics, Inc.

Effective: 2026-06-18
Successor: Jonathan Gillis
Filed: June 18, 2026, 5:00 PM ET

Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.

Appointed (interim)

Jonathan Gillis

interim Chief Financial Officer

MPLT · MapLight Therapeutics, Inc.

Effective: 2026-06-18
Filed: June 18, 2026, 5:00 PM ET

the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vishwas Setia departed as Chief Financial Officer at MapLight Therapeutics, Inc..

Action: separated
Role: Chief Financial Officer

Exact text from the filing

Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc. (the “Company”), effective immediately, following a review of a human resources violation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Gillis was appointed as interim Chief Financial Officer at MapLight Therapeutics, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.

View on SEC.gov

MapLight Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-276065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.